The study identifies PIAS3 as a key promoter of ferroptosis in hepatocellular carcinoma (HCC) by regulating TXNIP through TGF-β signaling, suggesting a novel therapeutic target for enhancing ferroptotic sensitivity in HCC treatment. This evidence concerns the gene PIAS3 and hepatocellular carcinoma.